- Home
- BMY
as 04-25-2025 4:00pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 120.5B | IPO Year: | N/A |
| Target Price: | $58.93 | AVG Volume (30 days): | 15.2M |
| Analyst Decision: | Hold | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $63.33 | Next Earning Date: | 04-24-2025 |
| Revenue: | $47,636,000,000 | Revenue Growth: | 4.62% |
| Revenue Growth (this year): | -4.32% | Revenue Growth (next year): | -6.38% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Insider Monkey
17 hours ago
Bristol-Myers Squibb Company (BMY): A Growing Dividend Stock with Low PE Ratio
Argus Research
18 hours ago
Analyst Report: Bristol-Myers Squibb Co.
Argus Research
19 hours ago
Market Digest: GOLD, BMY, CSX, DFS, FE, GPC, GAP, HBAN, IBM, LRCX, NEM, T, TXN, ELV, KDP, GEV
Barrons.com
a day ago
Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy.
Morningstar Research
a day ago
Analyst Report: Bristol-Myers Squibb Company
Investor's Business Daily
a day ago
Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat
Barrons.com
a day ago
Dividends Could Be Under Threat. Here Are 9 Stocks With Safe 5% Yields.
MT Newswires
a day ago
JPMorgan Cuts Price Target on Bristol-Myers Squibb to $67 From $70
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.